PURPOSE Routine second transurethral resection (TUR) for non-muscle-invasive bladder cancer (NMIBC) is common practice in Germany. Applicability of European Organization for Research and Treatment of Cancer (EORTC) and Spanish Urological Club for Oncological Treatment (CUETO) models in NMIBC patients is still controversial. Aim of the study was to assess the performance of EORTC and CUETO predictive models in NMIBC patients treated with second TUR. METHODS 479 NMIBC patients with routine second TUR were analyzed retrospectively between 2003 and 2011, and investigated with clinical and pathological variables in regard to tumor recurrence and progression. Furthermore, recurrencefree survival (RFS) and progression-free survival (PFS) were evaluated according to EORTC and CUETO, and the discrimination of the models assessed. RESULTS With a median follow-up of 60 months, prior recurrence rate, grade, and second TUR pathology were independent prognostic factors for the risk of disease recurrence and progression. The concordance index of the EORTC and the CUETO model was 0.563 and 0.516 for recurrence and 0.681 and 0.702 for progression, respectively. The positive pathology after second TUR was significantly associated with risk of disease recurrence and progression. EORTC and CUETO risk models estimated progression better than recurrence, especially with higherscore groups. CONCLUSIONS Improved predictive tools should be developed for optimal treatment selection.

中文翻译：

---

EORTC风险表和CUETO评分模型可用于预测接受常规第二次经尿道切除术的非肌肉浸润性膀胱癌患者的复发和进展。

目的在德国，非肌肉浸润性膀胱癌（NMIBC）的常规第二次经尿道切除术（TUR）是很普遍的做法。欧洲癌症研究和治疗组织（EORTC）和西班牙泌尿外科肿瘤治疗俱乐部（CUETO）模型在NMIBC患者中的适用性仍存在争议。这项研究的目的是评估在接受第二次TUR治疗的NMIBC患者中EORTC和CUETO预测模型的表现。方法2003年至2011年间对479例常规第二次TUR的NMIBC患者进行回顾性分析，并就肿瘤的复发和进展进行了临床和病理学调查。此外，根据EORTC和CUETO评估了无复发生存期（RFS）和无进展生存期（PFS），并评估了模型的辨别力。结果中位随访60个月，先前的复发率，分级和第二TUR病理是疾病复发和进展风险的独立预后因素。EORTC和CUETO模型的一致性指数复发分别为0.563和0.516，进展指数分别为0.681和0.702。第二次TUR后的阳性病理与疾病复发和进展的风险显着相关。EORTC和CUETO风险模型估计进展优于复发，特别是评分较高的组。结论应开发改良的预测工具，以选择最佳治疗方案。EORTC和CUETO模型的一致性指数复发分别为0.563和0.516，进展指数分别为0.681和0.702。第二次TUR后的阳性病理与疾病复发和进展的风险显着相关。EORTC和CUETO风险模型估计进展优于复发，特别是评分较高的组。结论应开发改良的预测工具，以选择最佳治疗方案。EORTC和CUETO模型的一致性指数复发分别为0.563和0.516，进展指数分别为0.681和0.702。第二次TUR后的阳性病理与疾病复发和进展的风险显着相关。EORTC和CUETO风险模型估计进展优于复发，特别是评分较高的组。结论应开发改良的预测工具，以选择最佳治疗方案。